#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=The present study confirms that a remarkable number of patients with ACC who are operated on with radical intent are destined to relapse .
2-1	14-17	The	abstract[2]	new[2]	coref	5-2[23_2]
2-2	18-25	present	abstract[2]	new[2]	_	_
2-3	26-31	study	abstract[2]	new[2]	_	_
2-4	32-40	confirms	_	_	_	_
2-5	41-45	that	_	_	_	_
2-6	46-47	a	quantity[3]	new[3]	_	_
2-7	48-58	remarkable	quantity[3]	new[3]	_	_
2-8	59-65	number	quantity[3]	new[3]	_	_
2-9	66-68	of	quantity[3]	new[3]	_	_
2-10	69-77	patients	quantity[3]|person	new[3]|new	coref	8-8[52_0]
2-11	78-82	with	quantity[3]	new[3]	_	_
2-12	83-86	ACC	quantity[3]|abstract	new[3]|new	coref	12-12
2-13	87-90	who	_	_	_	_
2-14	91-94	are	_	_	_	_
2-15	95-103	operated	_	_	_	_
2-16	104-106	on	_	_	_	_
2-17	107-111	with	_	_	_	_
2-18	112-119	radical	abstract[6]	new[6]	_	_
2-19	120-126	intent	abstract[6]	new[6]	_	_
2-20	127-130	are	_	_	_	_
2-21	131-139	destined	_	_	_	_
2-22	140-142	to	_	_	_	_
2-23	143-150	relapse	_	_	_	_
2-24	151-152	.	_	_	_	_

#Text=ACC recurrence portends a worse prognosis and has a huge impact on quality of life ; therefore , investigators have considered the use of adjuvant mitotane therapy following surgical operation .
3-1	153-156	ACC	abstract[7]	new[7]	coref	12-12[85_7]
3-2	157-167	recurrence	abstract[7]	new[7]	_	_
3-3	168-176	portends	_	_	_	_
3-4	177-178	a	abstract[8]	new[8]	_	_
3-5	179-184	worse	abstract[8]	new[8]	_	_
3-6	185-194	prognosis	abstract[8]	new[8]	_	_
3-7	195-198	and	_	_	_	_
3-8	199-202	has	_	_	_	_
3-9	203-204	a	abstract[9]	new[9]	coref	15-11[112_9]
3-10	205-209	huge	abstract[9]	new[9]	_	_
3-11	210-216	impact	abstract[9]	new[9]	_	_
3-12	217-219	on	abstract[9]	new[9]	_	_
3-13	220-227	quality	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-14	228-230	of	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-15	231-235	life	abstract[9]|abstract[10]|abstract	new[9]|new[10]|new	_	_
3-16	236-237	;	_	_	_	_
3-17	238-247	therefore	_	_	_	_
3-18	248-249	,	_	_	_	_
3-19	250-263	investigators	person	new	_	_
3-20	264-268	have	_	_	_	_
3-21	269-279	considered	_	_	_	_
3-22	280-283	the	abstract[13]	new[13]	_	_
3-23	284-287	use	abstract[13]	new[13]	_	_
3-24	288-290	of	abstract[13]	new[13]	_	_
3-25	291-299	adjuvant	abstract[13]|abstract|abstract[16]	new[13]|new|new[16]	coref|coref	8-24|8-24[57_16]
3-26	300-308	mitotane	abstract[13]|abstract|abstract[16]	new[13]|new|new[16]	coref	4-14[22_0]
3-27	309-316	therapy	abstract[13]|abstract[16]	new[13]|new[16]	_	_
3-28	317-326	following	_	_	_	_
3-29	327-335	surgical	event[17]	new[17]	_	_
3-30	336-345	operation	event[17]	new[17]	_	_
3-31	346-347	.	_	_	_	_

#Text=However , a limited number of often small-sized studies reporting the outcome of adjuvant mitotane is available .
4-1	348-355	However	_	_	_	_
4-2	356-357	,	_	_	_	_
4-3	358-359	a	quantity[18]	new[18]	_	_
4-4	360-367	limited	quantity[18]	new[18]	_	_
4-5	368-374	number	quantity[18]	new[18]	_	_
4-6	375-377	of	quantity[18]	new[18]	_	_
4-7	378-383	often	quantity[18]|event[19]	new[18]|new[19]	coref	6-1[33_19]
4-8	384-395	small-sized	quantity[18]|event[19]	new[18]|new[19]	_	_
4-9	396-403	studies	quantity[18]|event[19]	new[18]|new[19]	_	_
4-10	404-413	reporting	_	_	_	_
4-11	414-417	the	event[20]	new[20]	coref	5-15[29_20]
4-12	418-425	outcome	event[20]	new[20]	_	_
4-13	426-428	of	event[20]	new[20]	_	_
4-14	429-437	adjuvant	event[20]|person|abstract[22]	new[20]|new|giv[22]	coref|coref	5-12[0_22]|10-14
4-15	438-446	mitotane	event[20]|abstract[22]	new[20]|giv[22]	_	_
4-16	447-449	is	_	_	_	_
4-17	450-459	available	_	_	_	_
4-18	460-461	.	_	_	_	_

#Text=In the present study , we explored the relationship between target mitotane concentrations and patient outcome using the TTR , analogous to warfarin treatment .
5-1	462-464	In	_	_	_	_
5-2	465-468	the	abstract[23]	giv[23]	coref	11-2[68_23]
5-3	469-476	present	abstract[23]	giv[23]	_	_
5-4	477-482	study	abstract[23]	giv[23]	_	_
5-5	483-484	,	_	_	_	_
5-6	485-487	we	person	acc	ana	11-6
5-7	488-496	explored	_	_	_	_
5-8	497-500	the	abstract[25]	new[25]	coref	12-3[81_25]
5-9	501-513	relationship	abstract[25]	new[25]	_	_
5-10	514-521	between	abstract[25]	new[25]	_	_
5-11	522-528	target	abstract[25]|animal[27]	new[25]|new[27]	coref	14-6[98_27]
5-12	529-537	mitotane	abstract[25]|abstract|animal[27]	new[25]|giv|new[27]	coref	6-7
5-13	538-552	concentrations	abstract[25]|animal[27]	new[25]|new[27]	_	_
5-14	553-556	and	abstract[25]	new[25]	_	_
5-15	557-564	patient	abstract[25]|person|event[29]	new[25]|new|giv[29]	_	_
5-16	565-572	outcome	abstract[25]|event[29]	new[25]|giv[29]	_	_
5-17	573-578	using	_	_	_	_
5-18	579-582	the	abstract[30]	new[30]	coref	11-8[70_30]
5-19	583-586	TTR	abstract[30]	new[30]	_	_
5-20	587-588	,	_	_	_	_
5-21	589-598	analogous	_	_	_	_
5-22	599-601	to	_	_	_	_
5-23	602-610	warfarin	person|event[32]	new|new[32]	coref	10-14[67_32]
5-24	611-620	treatment	event[32]	new[32]	_	_
5-25	621-622	.	_	_	_	_

#Text=Some previous studies used the peak mitotane level , which cannot give an adequate representation since it is a measurement at a single point in time .
6-1	623-627	Some	event[33]	giv[33]	coref	7-2[41_33]
6-2	628-636	previous	event[33]	giv[33]	_	_
6-3	637-644	studies	event[33]	giv[33]	_	_
6-4	645-649	used	_	_	_	_
6-5	650-653	the	quantity[36]	new[36]	coref	9-9[60_36]
6-6	654-658	peak	place|quantity[36]	new|new[36]	_	_
6-7	659-667	mitotane	abstract|quantity[36]	giv|new[36]	coref	7-8
6-8	668-673	level	quantity[36]	new[36]	_	_
6-9	674-675	,	_	_	_	_
6-10	676-681	which	_	_	_	_
6-11	682-688	cannot	_	_	_	_
6-12	689-693	give	_	_	_	_
6-13	694-696	an	abstract[37]	new[37]	ana	6-17[0_37]
6-14	697-705	adequate	abstract[37]	new[37]	_	_
6-15	706-720	representation	abstract[37]	new[37]	_	_
6-16	721-726	since	_	_	_	_
6-17	727-729	it	abstract	giv	coref	6-19[39_0]
6-18	730-732	is	_	_	_	_
6-19	733-734	a	abstract[39]	giv[39]	coref	11-16[73_39]
6-20	735-746	measurement	abstract[39]	giv[39]	_	_
6-21	747-749	at	abstract[39]	giv[39]	_	_
6-22	750-751	a	abstract[39]|time[40]	giv[39]|new[40]	coref	18-3[136_40]
6-23	752-758	single	abstract[39]|time[40]	giv[39]|new[40]	_	_
6-24	759-764	point	abstract[39]|time[40]	giv[39]|new[40]	_	_
6-25	765-767	in	abstract[39]|time[40]	giv[39]|new[40]	_	_
6-26	768-772	time	abstract[39]|time[40]	giv[39]|new[40]	_	_
6-27	773-774	.	_	_	_	_

#Text=In other studies , the percentage of mitotane measurements in a range was used , but this method has the caveat of being strongly dependent on the number of available measurements .
7-1	775-777	In	_	_	_	_
7-2	778-783	other	event[41]	giv[41]	_	_
7-3	784-791	studies	event[41]	giv[41]	_	_
7-4	792-793	,	_	_	_	_
7-5	794-797	the	abstract[42]	new[42]	coref	9-10[0_42]
7-6	798-808	percentage	abstract[42]	new[42]	_	_
7-7	809-811	of	abstract[42]	new[42]	_	_
7-8	812-820	mitotane	abstract[42]|abstract|abstract[44]	new[42]|giv|new[44]	coref|coref	7-30[49_44]|9-17
7-9	821-833	measurements	abstract[42]|abstract[44]	new[42]|new[44]	_	_
7-10	834-836	in	abstract[42]|abstract[44]	new[42]|new[44]	_	_
7-11	837-838	a	abstract[42]|abstract[44]|abstract[45]	new[42]|new[44]|new[45]	coref	17-25[133_45]
7-12	839-844	range	abstract[42]|abstract[44]|abstract[45]	new[42]|new[44]|new[45]	_	_
7-13	845-848	was	_	_	_	_
7-14	849-853	used	_	_	_	_
7-15	854-855	,	_	_	_	_
7-16	856-859	but	_	_	_	_
7-17	860-864	this	abstract[46]	new[46]	_	_
7-18	865-871	method	abstract[46]	new[46]	_	_
7-19	872-875	has	_	_	_	_
7-20	876-879	the	abstract[47]	new[47]	ana	8-1[0_47]
7-21	880-886	caveat	abstract[47]	new[47]	_	_
7-22	887-889	of	_	_	_	_
7-23	890-895	being	_	_	_	_
7-24	896-904	strongly	_	_	_	_
7-25	905-914	dependent	_	_	_	_
7-26	915-917	on	_	_	_	_
7-27	918-921	the	quantity[48]	new[48]	_	_
7-28	922-928	number	quantity[48]	new[48]	_	_
7-29	929-931	of	quantity[48]	new[48]	_	_
7-30	932-941	available	quantity[48]|abstract[49]	new[48]|giv[49]	_	_
7-31	942-954	measurements	quantity[48]|abstract[49]	new[48]|giv[49]	_	_
7-32	955-956	.	_	_	_	_

#Text=This may introduce a bias when comparing patients with different durations of follow-ups , which may be quite prolonged in the case of adjuvant therapy .
8-1	957-961	This	abstract	giv	_	_
8-2	962-965	may	_	_	_	_
8-3	966-975	introduce	_	_	_	_
8-4	976-977	a	abstract[51]	new[51]	_	_
8-5	978-982	bias	abstract[51]	new[51]	_	_
8-6	983-987	when	_	_	_	_
8-7	988-997	comparing	_	_	_	_
8-8	998-1006	patients	person[52]	giv[52]	coref	18-17[0_52]
8-9	1007-1011	with	person[52]	giv[52]	_	_
8-10	1012-1021	different	person[52]|abstract[53]	giv[52]|new[53]	_	_
8-11	1022-1031	durations	person[52]|abstract[53]	giv[52]|new[53]	_	_
8-12	1032-1034	of	person[52]|abstract[53]	giv[52]|new[53]	_	_
8-13	1035-1045	follow-ups	person[52]|abstract[53]|event	giv[52]|new[53]|new	_	_
8-14	1046-1047	,	_	_	_	_
8-15	1048-1053	which	_	_	_	_
8-16	1054-1057	may	_	_	_	_
8-17	1058-1060	be	_	_	_	_
8-18	1061-1066	quite	_	_	_	_
8-19	1067-1076	prolonged	_	_	_	_
8-20	1077-1079	in	_	_	_	_
8-21	1080-1083	the	abstract[55]	new[55]	_	_
8-22	1084-1088	case	abstract[55]	new[55]	_	_
8-23	1089-1091	of	abstract[55]	new[55]	_	_
8-24	1092-1100	adjuvant	abstract[55]|abstract|abstract[57]	new[55]|giv|giv[57]	coref	24-15[200_57]
8-25	1101-1108	therapy	abstract[55]|abstract[57]	new[55]|giv[57]	_	_
8-26	1109-1110	.	_	_	_	_

#Text=Moreover , there is no evidence to define what percentage level identifies a good exposure to mitotane .
9-1	1111-1119	Moreover	_	_	_	_
9-2	1120-1121	,	_	_	_	_
9-3	1122-1127	there	_	_	_	_
9-4	1128-1130	is	_	_	_	_
9-5	1131-1133	no	abstract[58]	new[58]	_	_
9-6	1134-1142	evidence	abstract[58]	new[58]	_	_
9-7	1143-1145	to	_	_	_	_
9-8	1146-1152	define	_	_	_	_
9-9	1153-1157	what	quantity[60]	giv[60]	coref	14-19[103_60]
9-10	1158-1168	percentage	abstract|quantity[60]	giv|giv[60]	_	_
9-11	1169-1174	level	quantity[60]	giv[60]	_	_
9-12	1175-1185	identifies	_	_	_	_
9-13	1186-1187	a	abstract[61]	new[61]	coref	11-21[74_61]
9-14	1188-1192	good	abstract[61]	new[61]	_	_
9-15	1193-1201	exposure	abstract[61]	new[61]	_	_
9-16	1202-1204	to	abstract[61]	new[61]	_	_
9-17	1205-1213	mitotane	abstract[61]|abstract	new[61]|giv	coref	11-24
9-18	1214-1215	.	_	_	_	_

#Text=These methodological issues may have contributed to the discrepancy in the literature concerning adjuvant treatment .
10-1	1216-1221	These	abstract[63]	new[63]	_	_
10-2	1222-1236	methodological	abstract[63]	new[63]	_	_
10-3	1237-1243	issues	abstract[63]	new[63]	_	_
10-4	1244-1247	may	_	_	_	_
10-5	1248-1252	have	_	_	_	_
10-6	1253-1264	contributed	_	_	_	_
10-7	1265-1267	to	_	_	_	_
10-8	1268-1271	the	abstract[64]	new[64]	_	_
10-9	1272-1283	discrepancy	abstract[64]	new[64]	_	_
10-10	1284-1286	in	abstract[64]	new[64]	_	_
10-11	1287-1290	the	abstract[64]|abstract[65]	new[64]|new[65]	_	_
10-12	1291-1301	literature	abstract[64]|abstract[65]	new[64]|new[65]	_	_
10-13	1302-1312	concerning	_	_	_	_
10-14	1313-1321	adjuvant	person|event[67]	giv|giv[67]	coref|coref	13-18|14-13[101_67]
10-15	1322-1331	treatment	event[67]	giv[67]	_	_
10-16	1332-1333	.	_	_	_	_

#Text=In the present study , we calculated the TTR , which in our opinion gives a more adequate representation of chronic exposure to mitotane , and analyzed the results in a multivariate analysis without predefining arbitrary cutoff values .
11-1	1334-1336	In	_	_	_	_
11-2	1337-1340	the	abstract[68]	giv[68]	coref	23-22[0_68]
11-3	1341-1348	present	abstract[68]	giv[68]	_	_
11-4	1349-1354	study	abstract[68]	giv[68]	_	_
11-5	1355-1356	,	_	_	_	_
11-6	1357-1359	we	person	giv	ana	11-13
11-7	1360-1370	calculated	_	_	_	_
11-8	1371-1374	the	abstract[70]	giv[70]	coref	12-7[82_70]
11-9	1375-1378	TTR	abstract[70]	giv[70]	_	_
11-10	1379-1380	,	_	_	_	_
11-11	1381-1386	which	_	_	_	_
11-12	1387-1389	in	_	_	_	_
11-13	1390-1393	our	person|abstract[72]	giv|new[72]	ana	12-1
11-14	1394-1401	opinion	abstract[72]	new[72]	_	_
11-15	1402-1407	gives	_	_	_	_
11-16	1408-1409	a	abstract[73]	giv[73]	_	_
11-17	1410-1414	more	abstract[73]	giv[73]	_	_
11-18	1415-1423	adequate	abstract[73]	giv[73]	_	_
11-19	1424-1438	representation	abstract[73]	giv[73]	_	_
11-20	1439-1441	of	abstract[73]	giv[73]	_	_
11-21	1442-1449	chronic	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
11-22	1450-1458	exposure	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
11-23	1459-1461	to	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
11-24	1462-1470	mitotane	abstract[73]|abstract[74]|abstract	giv[73]|giv[74]|giv	coref	13-8
11-25	1471-1472	,	_	_	_	_
11-26	1473-1476	and	_	_	_	_
11-27	1477-1485	analyzed	_	_	_	_
11-28	1486-1489	the	abstract[76]	new[76]	coref	30-15[255_76]
11-29	1490-1497	results	abstract[76]	new[76]	_	_
11-30	1498-1500	in	abstract[76]	new[76]	_	_
11-31	1501-1502	a	abstract[76]|abstract[77]	new[76]|new[77]	coref	30-9[253_77]
11-32	1503-1515	multivariate	abstract[76]|abstract[77]	new[76]|new[77]	_	_
11-33	1516-1524	analysis	abstract[76]|abstract[77]	new[76]|new[77]	_	_
11-34	1525-1532	without	_	_	_	_
11-35	1533-1544	predefining	_	_	_	_
11-36	1545-1554	arbitrary	abstract[79]	new[79]	_	_
11-37	1555-1561	cutoff	abstract|abstract[79]	new|new[79]	_	_
11-38	1562-1568	values	abstract[79]	new[79]	_	_
11-39	1569-1570	.	_	_	_	_

#Text=We found an inverse relationship between the TTR and risk of ACC recurrence , implying that the greater the TTR , the lower the risk .
12-1	1571-1573	We	person	giv	ana	14-17
12-2	1574-1579	found	_	_	_	_
12-3	1580-1582	an	abstract[81]	giv[81]	coref	21-3[160_81]
12-4	1583-1590	inverse	abstract[81]	giv[81]	_	_
12-5	1591-1603	relationship	abstract[81]	giv[81]	_	_
12-6	1604-1611	between	abstract[81]	giv[81]	_	_
12-7	1612-1615	the	abstract[81]|abstract[82]	giv[81]|giv[82]	coref	12-19[86_82]
12-8	1616-1619	TTR	abstract[81]|abstract[82]	giv[81]|giv[82]	_	_
12-9	1620-1623	and	abstract[81]	giv[81]	_	_
12-10	1624-1628	risk	abstract[81]|abstract[83]	giv[81]|new[83]	coref	12-24[87_83]
12-11	1629-1631	of	abstract[81]|abstract[83]	giv[81]|new[83]	_	_
12-12	1632-1635	ACC	abstract[81]|abstract[83]|abstract|abstract[85]	giv[81]|new[83]|giv|giv[85]	coref|coref	15-17|15-17[115_85]
12-13	1636-1646	recurrence	abstract[81]|abstract[83]|abstract[85]	giv[81]|new[83]|giv[85]	_	_
12-14	1647-1648	,	_	_	_	_
12-15	1649-1657	implying	_	_	_	_
12-16	1658-1662	that	_	_	_	_
12-17	1663-1666	the	_	_	_	_
12-18	1667-1674	greater	_	_	_	_
12-19	1675-1678	the	abstract[86]	giv[86]	_	_
12-20	1679-1682	TTR	abstract[86]	giv[86]	_	_
12-21	1683-1684	,	_	_	_	_
12-22	1685-1688	the	_	_	_	_
12-23	1689-1694	lower	_	_	_	_
12-24	1695-1698	the	abstract[87]	giv[87]	_	_
12-25	1699-1703	risk	abstract[87]	giv[87]	_	_
12-26	1704-1705	.	_	_	_	_

#Text=This finding supports the clinical value of mitotane monitoring and the concept of target doses in the adjuvant setting .
13-1	1706-1710	This	abstract[88]	new[88]	coref	21-22[167_88]
13-2	1711-1718	finding	abstract[88]	new[88]	_	_
13-3	1719-1727	supports	_	_	_	_
13-4	1728-1731	the	abstract[89]	new[89]	_	_
13-5	1732-1740	clinical	abstract[89]	new[89]	_	_
13-6	1741-1746	value	abstract[89]	new[89]	_	_
13-7	1747-1749	of	abstract[89]	new[89]	_	_
13-8	1750-1758	mitotane	abstract[89]|abstract|abstract[91]	new[89]|giv|new[91]	coref|coref	14-7|19-24[150_91]
13-9	1759-1769	monitoring	abstract[89]|abstract[91]	new[89]|new[91]	_	_
13-10	1770-1773	and	_	_	_	_
13-11	1774-1777	the	abstract[92]	new[92]	coref	16-5[119_92]
13-12	1778-1785	concept	abstract[92]	new[92]	_	_
13-13	1786-1788	of	abstract[92]	new[92]	_	_
13-14	1789-1795	target	abstract[92]|quantity[93]	new[92]|new[93]	coref	22-3[176_93]
13-15	1796-1801	doses	abstract[92]|quantity[93]	new[92]|new[93]	_	_
13-16	1802-1804	in	abstract[92]|quantity[93]	new[92]|new[93]	_	_
13-17	1805-1808	the	abstract[92]|quantity[93]|abstract[95]	new[92]|new[93]|new[95]	_	_
13-18	1809-1817	adjuvant	abstract[92]|quantity[93]|person|abstract[95]	new[92]|new[93]|giv|new[95]	coref	14-14
13-19	1818-1825	setting	abstract[92]|quantity[93]|abstract[95]	new[92]|new[93]|new[95]	_	_
13-20	1826-1827	.	_	_	_	_

#Text=Although it is plausible that lower mitotane concentrations may be effective in an adjuvant treatment , we analyzed only the level of 14 mg/L , because this was the target in our practice .
14-1	1828-1836	Although	_	_	_	_
14-2	1837-1839	it	abstract	new	cata	14-2[0_99]
14-3	1840-1842	is	_	_	_	_
14-4	1843-1852	plausible	_	_	_	_
14-5	1853-1857	that	abstract[99]	new[99]	ana	14-27[0_99]
14-6	1858-1863	lower	animal[98]|abstract[99]	giv[98]|new[99]	coref	15-6[111_98]
14-7	1864-1872	mitotane	abstract|animal[98]|abstract[99]	giv|giv[98]|new[99]	coref	15-7
14-8	1873-1887	concentrations	animal[98]|abstract[99]	giv[98]|new[99]	_	_
14-9	1888-1891	may	abstract[99]	new[99]	_	_
14-10	1892-1894	be	abstract[99]	new[99]	_	_
14-11	1895-1904	effective	abstract[99]	new[99]	_	_
14-12	1905-1907	in	_	_	_	_
14-13	1908-1910	an	event[101]	giv[101]	coref	17-13[0_101]
14-14	1911-1919	adjuvant	person|event[101]	giv|giv[101]	coref	23-8
14-15	1920-1929	treatment	event[101]	giv[101]	_	_
14-16	1930-1931	,	_	_	_	_
14-17	1932-1934	we	person	giv	ana	14-32
14-18	1935-1943	analyzed	_	_	_	_
14-19	1944-1948	only	quantity[103]	giv[103]	_	_
14-20	1949-1952	the	quantity[103]	giv[103]	_	_
14-21	1953-1958	level	quantity[103]	giv[103]	_	_
14-22	1959-1961	of	quantity[103]	giv[103]	_	_
14-23	1962-1964	14	quantity[103]|quantity[104]	giv[103]|new[104]	_	_
14-24	1965-1969	mg/L	quantity[103]|quantity[104]	giv[103]|new[104]	_	_
14-25	1970-1971	,	_	_	_	_
14-26	1972-1979	because	_	_	_	_
14-27	1980-1984	this	abstract	giv	coref	14-29[106_0]
14-28	1985-1988	was	_	_	_	_
14-29	1989-1992	the	abstract[106]	giv[106]	coref	17-26[0_106]
14-30	1993-1999	target	abstract[106]	giv[106]	_	_
14-31	2000-2002	in	abstract[106]	giv[106]	_	_
14-32	2003-2006	our	abstract[106]|person|abstract[108]	giv[106]|giv|new[108]	ana|coref	18-1|22-21[181_108]
14-33	2007-2015	practice	abstract[106]|abstract[108]	giv[106]|new[108]	_	_
14-34	2016-2017	.	_	_	_	_

#Text=The time needed to achieve target mitotane concentrations also has an impact on the risk of ACC recurrence : a longer time was associated with higher risk .
15-1	2018-2021	The	time[109]	new[109]	_	_
15-2	2022-2026	time	time[109]	new[109]	_	_
15-3	2027-2033	needed	_	_	_	_
15-4	2034-2036	to	_	_	_	_
15-5	2037-2044	achieve	event	new	coref|none	16-16[123_0]|15-5[0_123]
15-6	2045-2051	target	animal[111]	giv[111]	coref	18-11[138_111]
15-7	2052-2060	mitotane	abstract|animal[111]	giv|giv[111]	coref	16-8
15-8	2061-2075	concentrations	animal[111]	giv[111]	_	_
15-9	2076-2080	also	_	_	_	_
15-10	2081-2084	has	_	_	_	_
15-11	2085-2087	an	abstract[112]	giv[112]	_	_
15-12	2088-2094	impact	abstract[112]	giv[112]	_	_
15-13	2095-2097	on	abstract[112]	giv[112]	_	_
15-14	2098-2101	the	abstract[112]|abstract[113]	giv[112]|new[113]	coref	15-26[117_113]
15-15	2102-2106	risk	abstract[112]|abstract[113]	giv[112]|new[113]	_	_
15-16	2107-2109	of	abstract[112]|abstract[113]	giv[112]|new[113]	_	_
15-17	2110-2113	ACC	abstract[112]|abstract[113]|abstract|event[115]	giv[112]|new[113]|giv|giv[115]	coref|coref	18-22[0_115]|28-15
15-18	2114-2124	recurrence	abstract[112]|abstract[113]|event[115]	giv[112]|new[113]|giv[115]	_	_
15-19	2125-2126	:	_	_	_	_
15-20	2127-2128	a	time[116]	new[116]	coref	17-19[131_116]
15-21	2129-2135	longer	time[116]	new[116]	_	_
15-22	2136-2140	time	time[116]	new[116]	_	_
15-23	2141-2144	was	_	_	_	_
15-24	2145-2155	associated	_	_	_	_
15-25	2156-2160	with	_	_	_	_
15-26	2161-2167	higher	abstract[117]	giv[117]	ana	16-1[0_117]
15-27	2168-2172	risk	abstract[117]	giv[117]	_	_
15-28	2173-2174	.	_	_	_	_

#Text=This is consistent with the concept that mitotane is a slow-acting drug in relation to the achievement of significant plasma levels .
16-1	2175-2179	This	abstract	giv	_	_
16-2	2180-2182	is	_	_	_	_
16-3	2183-2193	consistent	_	_	_	_
16-4	2194-2198	with	_	_	_	_
16-5	2199-2202	the	abstract[119]	giv[119]	coref	21-28[169_119]
16-6	2203-2210	concept	abstract[119]	giv[119]	_	_
16-7	2211-2215	that	abstract[119]	giv[119]	_	_
16-8	2216-2224	mitotane	abstract[119]|substance	giv[119]|giv	coref	16-10[121_0]
16-9	2225-2227	is	abstract[119]	giv[119]	_	_
16-10	2228-2229	a	abstract[119]|substance[121]	giv[119]|giv[121]	coref	19-17[0_121]
16-11	2230-2241	slow-acting	abstract[119]|substance[121]	giv[119]|giv[121]	_	_
16-12	2242-2246	drug	abstract[119]|substance[121]	giv[119]|giv[121]	_	_
16-13	2247-2249	in	abstract[119]|substance[121]	giv[119]|giv[121]	_	_
16-14	2250-2258	relation	abstract[119]|substance[121]|abstract[122]	giv[119]|giv[121]|new[122]	_	_
16-15	2259-2261	to	abstract[119]|substance[121]|abstract[122]	giv[119]|giv[121]|new[122]	_	_
16-16	2262-2265	the	abstract[119]|substance[121]|abstract[122]|event[123]	giv[119]|giv[121]|new[122]|new[123]	_	_
16-17	2266-2277	achievement	abstract[119]|substance[121]|abstract[122]|event[123]	giv[119]|giv[121]|new[122]|new[123]	_	_
16-18	2278-2280	of	abstract[119]|substance[121]|abstract[122]|event[123]	giv[119]|giv[121]|new[122]|new[123]	_	_
16-19	2281-2292	significant	abstract[119]|substance[121]|abstract[122]|event[123]|abstract[125]	giv[119]|giv[121]|new[122]|new[123]|new[125]	coref	19-17[147_125]
16-20	2293-2299	plasma	abstract[119]|substance[121]|abstract[122]|event[123]|abstract|abstract[125]	giv[119]|giv[121]|new[122]|new[123]|new|new[125]	coref	21-12
16-21	2300-2306	levels	abstract[119]|substance[121]|abstract[122]|event[123]|abstract[125]	giv[119]|giv[121]|new[122]|new[123]|new[125]	_	_
16-22	2307-2308	.	_	_	_	_

#Text=Due to the very cautious dose titration in the starting phase of treatment employed in many centers , the time needed to get into the target range was exceedingly long .
17-1	2309-2312	Due	_	_	_	_
17-2	2313-2315	to	_	_	_	_
17-3	2316-2319	the	abstract[127]	new[127]	_	_
17-4	2320-2324	very	abstract[127]	new[127]	_	_
17-5	2325-2333	cautious	abstract[127]	new[127]	_	_
17-6	2334-2338	dose	quantity|abstract[127]	new|new[127]	coref	21-8[162_0]
17-7	2339-2348	titration	abstract[127]	new[127]	_	_
17-8	2349-2351	in	abstract[127]	new[127]	_	_
17-9	2352-2355	the	abstract[127]|abstract[128]	new[127]|new[128]	_	_
17-10	2356-2364	starting	abstract[127]|abstract[128]	new[127]|new[128]	_	_
17-11	2365-2370	phase	abstract[127]|abstract[128]	new[127]|new[128]	_	_
17-12	2371-2373	of	abstract[127]|abstract[128]	new[127]|new[128]	_	_
17-13	2374-2383	treatment	abstract[127]|abstract[128]|event	new[127]|new[128]|giv	coref	20-26
17-14	2384-2392	employed	_	_	_	_
17-15	2393-2395	in	_	_	_	_
17-16	2396-2400	many	place[130]	new[130]	coref	26-24[222_130]
17-17	2401-2408	centers	place[130]	new[130]	_	_
17-18	2409-2410	,	_	_	_	_
17-19	2411-2414	the	time[131]	giv[131]	coref	18-4[0_131]
17-20	2415-2419	time	time[131]	giv[131]	_	_
17-21	2420-2426	needed	_	_	_	_
17-22	2427-2429	to	_	_	_	_
17-23	2430-2433	get	_	_	_	_
17-24	2434-2438	into	_	_	_	_
17-25	2439-2442	the	abstract[133]	giv[133]	_	_
17-26	2443-2449	target	abstract|abstract[133]	giv|giv[133]	_	_
17-27	2450-2455	range	abstract[133]	giv[133]	_	_
17-28	2456-2459	was	_	_	_	_
17-29	2460-2471	exceedingly	_	_	_	_
17-30	2472-2476	long	_	_	_	_
17-31	2477-2478	.	_	_	_	_

#Text=We identified a time point at 17 months to achieve target concentrations , which significantly differentiates patients for their risk of recurrence .
18-1	2479-2481	We	person	giv	ana	21-1
18-2	2482-2492	identified	_	_	_	_
18-3	2493-2494	a	time[136]	giv[136]	_	_
18-4	2495-2499	time	time|time[136]	giv|giv[136]	_	_
18-5	2500-2505	point	time[136]	giv[136]	_	_
18-6	2506-2508	at	_	_	_	_
18-7	2509-2511	17	time[137]	new[137]	_	_
18-8	2512-2518	months	time[137]	new[137]	_	_
18-9	2519-2521	to	_	_	_	_
18-10	2522-2529	achieve	_	_	_	_
18-11	2530-2536	target	animal[138]	giv[138]	coref	21-11[164_138]
18-12	2537-2551	concentrations	animal[138]	giv[138]	_	_
18-13	2552-2553	,	_	_	_	_
18-14	2554-2559	which	_	_	_	_
18-15	2560-2573	significantly	_	_	_	_
18-16	2574-2588	differentiates	_	_	_	_
18-17	2589-2597	patients	person	giv	ana	18-19
18-18	2598-2601	for	_	_	_	_
18-19	2602-2607	their	person|abstract[141]	giv|new[141]	coref	22-11[178_0]
18-20	2608-2612	risk	abstract[141]	new[141]	_	_
18-21	2613-2615	of	abstract[141]	new[141]	_	_
18-22	2616-2626	recurrence	abstract[141]|abstract	new[141]|giv	coref	30-33[262_0]
18-23	2627-2628	.	_	_	_	_

#Text=The present findings call for a change in practice , aiming for a faster rise in mitotane levels and strengthening the value of mitotane monitoring .
19-1	2629-2632	The	abstract[143]	new[143]	coref	22-16[180_143]
19-2	2633-2640	present	abstract[143]	new[143]	_	_
19-3	2641-2649	findings	abstract[143]	new[143]	_	_
19-4	2650-2654	call	_	_	_	_
19-5	2655-2658	for	_	_	_	_
19-6	2659-2660	a	abstract[144]	new[144]	_	_
19-7	2661-2667	change	abstract[144]	new[144]	_	_
19-8	2668-2670	in	abstract[144]	new[144]	_	_
19-9	2671-2679	practice	abstract[144]	new[144]	_	_
19-10	2680-2681	,	_	_	_	_
19-11	2682-2688	aiming	_	_	_	_
19-12	2689-2692	for	_	_	_	_
19-13	2693-2694	a	abstract[145]	new[145]	_	_
19-14	2695-2701	faster	abstract[145]	new[145]	_	_
19-15	2702-2706	rise	abstract[145]	new[145]	_	_
19-16	2707-2709	in	abstract[145]	new[145]	_	_
19-17	2710-2718	mitotane	abstract[145]|abstract|abstract[147]	new[145]|giv|giv[147]	coref	19-24
19-18	2719-2725	levels	abstract[145]|abstract[147]	new[145]|giv[147]	_	_
19-19	2726-2729	and	_	_	_	_
19-20	2730-2743	strengthening	_	_	_	_
19-21	2744-2747	the	abstract[148]	new[148]	_	_
19-22	2748-2753	value	abstract[148]	new[148]	_	_
19-23	2754-2756	of	abstract[148]	new[148]	_	_
19-24	2757-2765	mitotane	abstract[148]|abstract|abstract[150]	new[148]|giv|giv[150]	coref	20-11
19-25	2766-2776	monitoring	abstract[148]|abstract[150]	new[148]|giv[150]	_	_
19-26	2777-2778	.	_	_	_	_

#Text=However , the potential danger of a rapid increment in mitotane dosing , which may result in important toxicity with consequent loss of compliance to treatment , should be considered .
20-1	2779-2786	However	_	_	_	_
20-2	2787-2788	,	_	_	_	_
20-3	2789-2792	the	quantity[151]	new[151]	_	_
20-4	2793-2802	potential	quantity[151]	new[151]	_	_
20-5	2803-2809	danger	quantity[151]	new[151]	_	_
20-6	2810-2812	of	quantity[151]	new[151]	_	_
20-7	2813-2814	a	quantity[151]|event[152]	new[151]|new[152]	_	_
20-8	2815-2820	rapid	quantity[151]|event[152]	new[151]|new[152]	_	_
20-9	2821-2830	increment	quantity[151]|event[152]	new[151]|new[152]	_	_
20-10	2831-2833	in	quantity[151]|event[152]	new[151]|new[152]	_	_
20-11	2834-2842	mitotane	quantity[151]|event[152]|abstract|quantity[154]	new[151]|new[152]|giv|new[154]	coref	21-8
20-12	2843-2849	dosing	quantity[151]|event[152]|quantity[154]	new[151]|new[152]|new[154]	_	_
20-13	2850-2851	,	_	_	_	_
20-14	2852-2857	which	_	_	_	_
20-15	2858-2861	may	_	_	_	_
20-16	2862-2868	result	_	_	_	_
20-17	2869-2871	in	_	_	_	_
20-18	2872-2881	important	abstract[155]	new[155]	coref	23-5[0_155]
20-19	2882-2890	toxicity	abstract[155]	new[155]	_	_
20-20	2891-2895	with	_	_	_	_
20-21	2896-2906	consequent	abstract[156]	new[156]	_	_
20-22	2907-2911	loss	abstract[156]	new[156]	_	_
20-23	2912-2914	of	abstract[156]	new[156]	_	_
20-24	2915-2925	compliance	abstract[156]|abstract[157]	new[156]|new[157]	_	_
20-25	2926-2928	to	abstract[156]|abstract[157]	new[156]|new[157]	_	_
20-26	2929-2938	treatment	abstract[156]|abstract[157]|event	new[156]|new[157]|giv	coref	21-19
20-27	2939-2940	,	_	_	_	_
20-28	2941-2947	should	_	_	_	_
20-29	2948-2950	be	_	_	_	_
20-30	2951-2961	considered	_	_	_	_
20-31	2962-2963	.	_	_	_	_

#Text=We found only a weak relationship between mitotane dose and its plasma concentrations during the first phase of treatment , and this finding is in agreement with the concept that individual differences in mitotane metabolism and other still unknown factors influence plasma concentrations .
21-1	2964-2966	We	person	giv	ana	23-2
21-2	2967-2972	found	_	_	_	_
21-3	2973-2977	only	abstract[160]	giv[160]	_	_
21-4	2978-2979	a	abstract[160]	giv[160]	_	_
21-5	2980-2984	weak	abstract[160]	giv[160]	_	_
21-6	2985-2997	relationship	abstract[160]	giv[160]	_	_
21-7	2998-3005	between	abstract[160]	giv[160]	_	_
21-8	3006-3014	mitotane	abstract[160]|abstract|quantity[162]	giv[160]|giv|giv[162]	coref|coref	21-34|24-28[203_162]
21-9	3015-3019	dose	abstract[160]|quantity[162]	giv[160]|giv[162]	_	_
21-10	3020-3023	and	abstract[160]	giv[160]	_	_
21-11	3024-3027	its	abstract[160]|animal[164]	giv[160]|giv[164]	coref	21-42[175_164]
21-12	3028-3034	plasma	abstract[160]|substance|animal[164]	giv[160]|giv|giv[164]	coref	21-42
21-13	3035-3049	concentrations	abstract[160]|animal[164]	giv[160]|giv[164]	_	_
21-14	3050-3056	during	_	_	_	_
21-15	3057-3060	the	abstract[165]	new[165]	coref	24-39[207_165]
21-16	3061-3066	first	abstract[165]	new[165]	_	_
21-17	3067-3072	phase	abstract[165]	new[165]	_	_
21-18	3073-3075	of	abstract[165]	new[165]	_	_
21-19	3076-3085	treatment	abstract[165]|event	new[165]|giv	coref	24-6
21-20	3086-3087	,	_	_	_	_
21-21	3088-3091	and	_	_	_	_
21-22	3092-3096	this	abstract[167]	giv[167]	_	_
21-23	3097-3104	finding	abstract[167]	giv[167]	_	_
21-24	3105-3107	is	_	_	_	_
21-25	3108-3110	in	_	_	_	_
21-26	3111-3120	agreement	abstract[168]	new[168]	_	_
21-27	3121-3125	with	abstract[168]	new[168]	_	_
21-28	3126-3129	the	abstract[168]|abstract[169]	new[168]|giv[169]	_	_
21-29	3130-3137	concept	abstract[168]|abstract[169]	new[168]|giv[169]	_	_
21-30	3138-3142	that	abstract[168]|abstract[169]	new[168]|giv[169]	_	_
21-31	3143-3153	individual	abstract[168]|abstract[169]|abstract[170]	new[168]|giv[169]|new[170]	_	_
21-32	3154-3165	differences	abstract[168]|abstract[169]|abstract[170]	new[168]|giv[169]|new[170]	_	_
21-33	3166-3168	in	abstract[168]|abstract[169]|abstract[170]	new[168]|giv[169]|new[170]	_	_
21-34	3169-3177	mitotane	abstract[168]|abstract[169]|abstract[170]|abstract|abstract[172]	new[168]|giv[169]|new[170]|giv|new[172]	coref|coref	23-8[186_0]|27-32[230_172]
21-35	3178-3188	metabolism	abstract[168]|abstract[169]|abstract[170]|abstract[172]	new[168]|giv[169]|new[170]|new[172]	_	_
21-36	3189-3192	and	abstract[168]|abstract[169]|abstract[170]	new[168]|giv[169]|new[170]	_	_
21-37	3193-3198	other	abstract[168]|abstract[169]|abstract[170]|abstract[173]	new[168]|giv[169]|new[170]|new[173]	coref	27-29[228_173]
21-38	3199-3204	still	abstract[168]|abstract[169]|abstract[170]|abstract[173]	new[168]|giv[169]|new[170]|new[173]	_	_
21-39	3205-3212	unknown	abstract[168]|abstract[169]|abstract[170]|abstract[173]	new[168]|giv[169]|new[170]|new[173]	_	_
21-40	3213-3220	factors	abstract[168]|abstract[169]|abstract[170]|abstract[173]	new[168]|giv[169]|new[170]|new[173]	_	_
21-41	3221-3230	influence	abstract[168]|abstract[169]	new[168]|giv[169]	_	_
21-42	3231-3237	plasma	abstract[168]|abstract[169]|substance|animal[175]	new[168]|giv[169]|giv|giv[175]	coref	27-19[226_175]
21-43	3238-3252	concentrations	abstract[168]|abstract[169]|animal[175]	new[168]|giv[169]|giv[175]	_	_
21-44	3253-3254	.	_	_	_	_

#Text=Interestingly , higher doses were employed in men and in patients with greater BMI and these novel findings matter for clinical practice .
22-1	3255-3268	Interestingly	_	_	_	_
22-2	3269-3270	,	_	_	_	_
22-3	3271-3277	higher	quantity[176]	giv[176]	coref	24-24[202_176]
22-4	3278-3283	doses	quantity[176]	giv[176]	_	_
22-5	3284-3288	were	_	_	_	_
22-6	3289-3297	employed	_	_	_	_
22-7	3298-3300	in	_	_	_	_
22-8	3301-3304	men	person	new	_	_
22-9	3305-3308	and	_	_	_	_
22-10	3309-3311	in	_	_	_	_
22-11	3312-3320	patients	person[178]	giv[178]	coref	23-29[193_178]
22-12	3321-3325	with	person[178]	giv[178]	_	_
22-13	3326-3333	greater	person[178]|abstract[179]	giv[178]|new[179]	_	_
22-14	3334-3337	BMI	person[178]|abstract[179]	giv[178]|new[179]	_	_
22-15	3338-3341	and	_	_	_	_
22-16	3342-3347	these	abstract[180]	giv[180]	_	_
22-17	3348-3353	novel	abstract[180]	giv[180]	_	_
22-18	3354-3362	findings	abstract[180]	giv[180]	_	_
22-19	3363-3369	matter	_	_	_	_
22-20	3370-3373	for	_	_	_	_
22-21	3374-3382	clinical	abstract[181]	giv[181]	coref	29-28[250_181]
22-22	3383-3391	practice	abstract[181]	giv[181]	_	_
22-23	3392-3393	.	_	_	_	_

#Text=In our cohort , toxicity associated with adjuvant mitotane was acceptable , though we acknowledge the fact that due to the study inclusion criteria we did not capture the patients who eventually discontinued mitotane in the first six months .
23-1	3394-3396	In	_	_	_	_
23-2	3397-3400	our	person|person[183]	giv|new[183]	ana	23-14
23-3	3401-3407	cohort	person[183]	new[183]	_	_
23-4	3408-3409	,	_	_	_	_
23-5	3410-3418	toxicity	abstract	giv	coref	24-1[196_0]
23-6	3419-3429	associated	_	_	_	_
23-7	3430-3434	with	_	_	_	_
23-8	3435-3443	adjuvant	person|abstract[186]	giv|giv[186]	coref|coref	23-34[0_186]|25-13
23-9	3444-3452	mitotane	abstract[186]	giv[186]	_	_
23-10	3453-3456	was	_	_	_	_
23-11	3457-3467	acceptable	_	_	_	_
23-12	3468-3469	,	_	_	_	_
23-13	3470-3476	though	_	_	_	_
23-14	3477-3479	we	person	giv	ana	23-25
23-15	3480-3491	acknowledge	_	_	_	_
23-16	3492-3495	the	abstract[188]	new[188]	_	_
23-17	3496-3500	fact	abstract[188]	new[188]	_	_
23-18	3501-3505	that	abstract[188]	new[188]	_	_
23-19	3506-3509	due	abstract[188]	new[188]	_	_
23-20	3510-3512	to	_	_	_	_
23-21	3513-3516	the	abstract[191]	new[191]	coref	31-1[264_191]
23-22	3517-3522	study	abstract|abstract[191]	giv|new[191]	coref	25-3[208_0]
23-23	3523-3532	inclusion	person|abstract[191]	new|new[191]	coref	31-2
23-24	3533-3541	criteria	abstract[191]	new[191]	_	_
23-25	3542-3544	we	person	giv	ana	30-3
23-26	3545-3548	did	_	_	_	_
23-27	3549-3552	not	_	_	_	_
23-28	3553-3560	capture	abstract	new	coref|none	29-4[245_0]|23-28[0_245]
23-29	3561-3564	the	person[193]	giv[193]	coref	24-11[199_193]
23-30	3565-3573	patients	person[193]	giv[193]	_	_
23-31	3574-3577	who	_	_	_	_
23-32	3578-3588	eventually	_	_	_	_
23-33	3589-3601	discontinued	_	_	_	_
23-34	3602-3610	mitotane	abstract	giv	coref	25-13[211_0]
23-35	3611-3613	in	_	_	_	_
23-36	3614-3617	the	time[195]	new[195]	coref	30-26[258_195]
23-37	3618-3623	first	time[195]	new[195]	_	_
23-38	3624-3627	six	time[195]	new[195]	_	_
23-39	3628-3634	months	time[195]	new[195]	_	_
23-40	3635-3636	.	_	_	_	_

#Text=Severe toxicity leading to permanent treatment discontinuation was recorded in only five patients on chronic therapy , and this is likely due to the low doses ( median dose of 2 g/day ) used to continue treatment in the maintenance phase .
24-1	3637-3643	Severe	abstract[196]	giv[196]	coref	27-13[225_196]
24-2	3644-3652	toxicity	abstract[196]	giv[196]	_	_
24-3	3653-3660	leading	_	_	_	_
24-4	3661-3663	to	_	_	_	_
24-5	3664-3673	permanent	event[198]	new[198]	_	_
24-6	3674-3683	treatment	event|event[198]	giv|new[198]	coref	24-37
24-7	3684-3699	discontinuation	event[198]	new[198]	_	_
24-8	3700-3703	was	_	_	_	_
24-9	3704-3712	recorded	_	_	_	_
24-10	3713-3715	in	_	_	_	_
24-11	3716-3720	only	person[199]	giv[199]	coref	25-8[209_199]
24-12	3721-3725	five	person[199]	giv[199]	_	_
24-13	3726-3734	patients	person[199]	giv[199]	_	_
24-14	3735-3737	on	person[199]	giv[199]	_	_
24-15	3738-3745	chronic	person[199]|abstract[200]	giv[199]|giv[200]	ana	24-19[0_200]
24-16	3746-3753	therapy	person[199]|abstract[200]	giv[199]|giv[200]	_	_
24-17	3754-3755	,	_	_	_	_
24-18	3756-3759	and	_	_	_	_
24-19	3760-3764	this	abstract	giv	_	_
24-20	3765-3767	is	_	_	_	_
24-21	3768-3774	likely	_	_	_	_
24-22	3775-3778	due	_	_	_	_
24-23	3779-3781	to	_	_	_	_
24-24	3782-3785	the	quantity[202]	giv[202]	_	_
24-25	3786-3789	low	quantity[202]	giv[202]	_	_
24-26	3790-3795	doses	quantity[202]	giv[202]	_	_
24-27	3796-3797	(	_	_	_	_
24-28	3798-3804	median	quantity[203]	giv[203]	_	_
24-29	3805-3809	dose	quantity[203]	giv[203]	_	_
24-30	3810-3812	of	quantity[203]	giv[203]	_	_
24-31	3813-3814	2	quantity[203]|quantity[204]	giv[203]|new[204]	_	_
24-32	3815-3820	g/day	quantity[203]|quantity[204]	giv[203]|new[204]	_	_
24-33	3821-3822	)	_	_	_	_
24-34	3823-3827	used	_	_	_	_
24-35	3828-3830	to	_	_	_	_
24-36	3831-3839	continue	_	_	_	_
24-37	3840-3849	treatment	event	giv	coref	25-20
24-38	3850-3852	in	_	_	_	_
24-39	3853-3856	the	abstract[207]	giv[207]	_	_
24-40	3857-3868	maintenance	abstract|abstract[207]	new|giv[207]	_	_
24-41	3869-3874	phase	abstract[207]	giv[207]	_	_
24-42	3875-3876	.	_	_	_	_

#Text=Thus , the present study shows that a few patients cannot tolerate adjuvant mitotane following the first months of treatment , proving than a careful follow-up is necessary .
25-1	3877-3881	Thus	_	_	_	_
25-2	3882-3883	,	_	_	_	_
25-3	3884-3887	the	abstract[208]	giv[208]	coref	28-3[232_208]
25-4	3888-3895	present	abstract[208]	giv[208]	_	_
25-5	3896-3901	study	abstract[208]	giv[208]	_	_
25-6	3902-3907	shows	_	_	_	_
25-7	3908-3912	that	_	_	_	_
25-8	3913-3914	a	person[209]	giv[209]	coref	26-20[0_209]
25-9	3915-3918	few	person[209]	giv[209]	_	_
25-10	3919-3927	patients	person[209]	giv[209]	_	_
25-11	3928-3934	cannot	_	_	_	_
25-12	3935-3943	tolerate	_	_	_	_
25-13	3944-3952	adjuvant	person|abstract[211]	giv|giv[211]	coref|coref	26-2[0_211]|28-11
25-14	3953-3961	mitotane	abstract[211]	giv[211]	_	_
25-15	3962-3971	following	_	_	_	_
25-16	3972-3975	the	time[212]	new[212]	_	_
25-17	3976-3981	first	time[212]	new[212]	_	_
25-18	3982-3988	months	time[212]	new[212]	_	_
25-19	3989-3991	of	time[212]	new[212]	_	_
25-20	3992-4001	treatment	time[212]|event	new[212]|giv	coref	26-14[219_0]
25-21	4002-4003	,	_	_	_	_
25-22	4004-4011	proving	_	_	_	_
25-23	4012-4016	than	_	_	_	_
25-24	4017-4018	a	event[214]	new[214]	_	_
25-25	4019-4026	careful	event[214]	new[214]	_	_
25-26	4027-4036	follow-up	event[214]	new[214]	_	_
25-27	4037-4039	is	_	_	_	_
25-28	4040-4049	necessary	_	_	_	_
25-29	4050-4051	.	_	_	_	_

#Text=Despite mitotane having a reputation for being a challenging drug to manage , adjuvant mitotane treatment is feasible when patients are managed in expert centers .
26-1	4052-4059	Despite	_	_	_	_
26-2	4060-4068	mitotane	abstract	giv	coref	26-8[217_0]
26-3	4069-4075	having	_	_	_	_
26-4	4076-4077	a	abstract[216]	new[216]	_	_
26-5	4078-4088	reputation	abstract[216]	new[216]	_	_
26-6	4089-4092	for	abstract[216]	new[216]	_	_
26-7	4093-4098	being	abstract[216]	new[216]	_	_
26-8	4099-4100	a	abstract[216]|substance[217]	new[216]|giv[217]	coref	26-15[0_217]
26-9	4101-4112	challenging	abstract[216]|substance[217]	new[216]|giv[217]	_	_
26-10	4113-4117	drug	abstract[216]|substance[217]	new[216]|giv[217]	_	_
26-11	4118-4120	to	_	_	_	_
26-12	4121-4127	manage	_	_	_	_
26-13	4128-4129	,	_	_	_	_
26-14	4130-4138	adjuvant	event[219]	giv[219]	coref	28-11[236_219]
26-15	4139-4147	mitotane	abstract|event[219]	giv|giv[219]	coref	27-9[224_0]
26-16	4148-4157	treatment	event[219]	giv[219]	_	_
26-17	4158-4160	is	_	_	_	_
26-18	4161-4169	feasible	_	_	_	_
26-19	4170-4174	when	_	_	_	_
26-20	4175-4183	patients	person	giv	coref	27-3[223_0]
26-21	4184-4187	are	_	_	_	_
26-22	4188-4195	managed	_	_	_	_
26-23	4196-4198	in	_	_	_	_
26-24	4199-4205	expert	person|place[222]	new|giv[222]	_	_
26-25	4206-4213	centers	place[222]	giv[222]	_	_
26-26	4214-4215	.	_	_	_	_

#Text=However , some patients were unable to tolerate the drug , exhibiting neurological toxicity even when exposed to “ normal ” mitotane concentrations , confirming the relevance of individual factors in mitotane metabolism .
27-1	4216-4223	However	_	_	_	_
27-2	4224-4225	,	_	_	_	_
27-3	4226-4230	some	person[223]	giv[223]	coref	28-15[238_223]
27-4	4231-4239	patients	person[223]	giv[223]	_	_
27-5	4240-4244	were	_	_	_	_
27-6	4245-4251	unable	_	_	_	_
27-7	4252-4254	to	_	_	_	_
27-8	4255-4263	tolerate	_	_	_	_
27-9	4264-4267	the	substance[224]	giv[224]	coref	27-32[0_224]
27-10	4268-4272	drug	substance[224]	giv[224]	_	_
27-11	4273-4274	,	_	_	_	_
27-12	4275-4285	exhibiting	_	_	_	_
27-13	4286-4298	neurological	abstract[225]	giv[225]	_	_
27-14	4299-4307	toxicity	abstract[225]	giv[225]	_	_
27-15	4308-4312	even	_	_	_	_
27-16	4313-4317	when	_	_	_	_
27-17	4318-4325	exposed	_	_	_	_
27-18	4326-4328	to	_	_	_	_
27-19	4329-4330	“	animal[226]	giv[226]	_	_
27-20	4331-4337	normal	animal[226]	giv[226]	_	_
27-21	4338-4339	”	animal[226]	giv[226]	_	_
27-22	4340-4348	mitotane	animal[226]	giv[226]	_	_
27-23	4349-4363	concentrations	animal[226]	giv[226]	_	_
27-24	4364-4365	,	_	_	_	_
27-25	4366-4376	confirming	_	_	_	_
27-26	4377-4380	the	abstract[227]	new[227]	_	_
27-27	4381-4390	relevance	abstract[227]	new[227]	_	_
27-28	4391-4393	of	abstract[227]	new[227]	_	_
27-29	4394-4404	individual	abstract[227]|abstract[228]	new[227]|giv[228]	_	_
27-30	4405-4412	factors	abstract[227]|abstract[228]	new[227]|giv[228]	_	_
27-31	4413-4415	in	abstract[227]|abstract[228]	new[227]|giv[228]	_	_
27-32	4416-4424	mitotane	abstract[227]|abstract[228]|abstract|abstract[230]	new[227]|giv[228]|giv|giv[230]	coref	28-12
27-33	4425-4435	metabolism	abstract[227]|abstract[228]|abstract[230]	new[227]|giv[228]|giv[230]	_	_
27-34	4436-4437	.	_	_	_	_

#Text=Strengths of the present study are the thorough characterization of adjuvant mitotane treatment of ACC patients following surgical removal of the tumor and the large data set , considering the rarity of the disease .
28-1	4438-4447	Strengths	abstract[231]	new[231]	coref	28-7[233_231]
28-2	4448-4450	of	abstract[231]	new[231]	_	_
28-3	4451-4454	the	abstract[231]|abstract[232]	new[231]|giv[232]	coref	31-5[265_232]
28-4	4455-4462	present	abstract[231]|abstract[232]	new[231]|giv[232]	_	_
28-5	4463-4468	study	abstract[231]|abstract[232]	new[231]|giv[232]	_	_
28-6	4469-4472	are	_	_	_	_
28-7	4473-4476	the	abstract[233]	giv[233]	_	_
28-8	4477-4485	thorough	abstract[233]	giv[233]	_	_
28-9	4486-4502	characterization	abstract[233]	giv[233]	_	_
28-10	4503-4505	of	abstract[233]	giv[233]	_	_
28-11	4506-4514	adjuvant	abstract[233]|person|event[236]	giv[233]|giv|giv[236]	coref	29-9[247_236]
28-12	4515-4523	mitotane	abstract[233]|abstract|event[236]	giv[233]|giv|giv[236]	_	_
28-13	4524-4533	treatment	abstract[233]|event[236]	giv[233]|giv[236]	_	_
28-14	4534-4536	of	abstract[233]|event[236]	giv[233]|giv[236]	_	_
28-15	4537-4540	ACC	abstract[233]|event[236]|organization|person[238]	giv[233]|giv[236]|giv|giv[238]	coref|coref	30-21[0_238]|30-34
28-16	4541-4549	patients	abstract[233]|event[236]|person[238]	giv[233]|giv[236]|giv[238]	_	_
28-17	4550-4559	following	_	_	_	_
28-18	4560-4568	surgical	event[239]	new[239]	ana	29-1[0_239]
28-19	4569-4576	removal	event[239]	new[239]	_	_
28-20	4577-4579	of	event[239]	new[239]	_	_
28-21	4580-4583	the	event[239]|object[240]	new[239]|new[240]	_	_
28-22	4584-4589	tumor	event[239]|object[240]	new[239]|new[240]	_	_
28-23	4590-4593	and	event[239]	new[239]	_	_
28-24	4594-4597	the	event[239]|abstract[241]	new[239]|new[241]	_	_
28-25	4598-4603	large	event[239]|abstract[241]	new[239]|new[241]	_	_
28-26	4604-4608	data	event[239]|abstract[241]	new[239]|new[241]	_	_
28-27	4609-4612	set	_	_	_	_
28-28	4613-4614	,	_	_	_	_
28-29	4615-4626	considering	_	_	_	_
28-30	4627-4630	the	abstract[242]	new[242]	_	_
28-31	4631-4637	rarity	abstract[242]	new[242]	_	_
28-32	4638-4640	of	abstract[242]	new[242]	_	_
28-33	4641-4644	the	abstract[242]|abstract[243]	new[242]|new[243]	_	_
28-34	4645-4652	disease	abstract[242]|abstract[243]	new[242]|new[243]	_	_
28-35	4653-4654	.	_	_	_	_

#Text=This allowed for the capture of details of mitotane treatment that were not available in previous studies and led to observations that may be useful to informing future practice .
29-1	4655-4659	This	event	giv	_	_
29-2	4660-4667	allowed	_	_	_	_
29-3	4668-4671	for	_	_	_	_
29-4	4672-4675	the	abstract[245]	new[245]	_	_
29-5	4676-4683	capture	abstract[245]	new[245]	_	_
29-6	4684-4686	of	abstract[245]	new[245]	_	_
29-7	4687-4694	details	abstract[245]|abstract[246]	new[245]|new[246]	_	_
29-8	4695-4697	of	abstract[245]|abstract[246]	new[245]|new[246]	_	_
29-9	4698-4706	mitotane	abstract[245]|abstract[246]|event[247]	new[245]|new[246]|giv[247]	coref	30-24[0_247]
29-10	4707-4716	treatment	abstract[245]|abstract[246]|event[247]	new[245]|new[246]|giv[247]	_	_
29-11	4717-4721	that	_	_	_	_
29-12	4722-4726	were	_	_	_	_
29-13	4727-4730	not	_	_	_	_
29-14	4731-4740	available	_	_	_	_
29-15	4741-4743	in	_	_	_	_
29-16	4744-4752	previous	abstract[248]	new[248]	_	_
29-17	4753-4760	studies	abstract[248]	new[248]	_	_
29-18	4761-4764	and	_	_	_	_
29-19	4765-4768	led	_	_	_	_
29-20	4769-4771	to	_	_	_	_
29-21	4772-4784	observations	abstract	new	_	_
29-22	4785-4789	that	_	_	_	_
29-23	4790-4793	may	_	_	_	_
29-24	4794-4796	be	_	_	_	_
29-25	4797-4803	useful	_	_	_	_
29-26	4804-4806	to	_	_	_	_
29-27	4807-4816	informing	_	_	_	_
29-28	4817-4823	future	abstract[250]	giv[250]	_	_
29-29	4824-4832	practice	abstract[250]	giv[250]	_	_
29-30	4833-4834	.	_	_	_	_

#Text=However , we should acknowledge the limits of a retrospective analysis , and that our results are not generalizable to patients who discontinue treatment within six months for intolerability or patients with early ACC recurrence .
30-1	4835-4842	However	_	_	_	_
30-2	4843-4844	,	_	_	_	_
30-3	4845-4847	we	person	giv	ana	30-15
30-4	4848-4854	should	_	_	_	_
30-5	4855-4866	acknowledge	_	_	_	_
30-6	4867-4870	the	abstract[252]	new[252]	_	_
30-7	4871-4877	limits	abstract[252]	new[252]	_	_
30-8	4878-4880	of	abstract[252]	new[252]	_	_
30-9	4881-4882	a	abstract[252]|abstract[253]	new[252]|giv[253]	_	_
30-10	4883-4896	retrospective	abstract[252]|abstract[253]	new[252]|giv[253]	_	_
30-11	4897-4905	analysis	abstract[252]|abstract[253]	new[252]|giv[253]	_	_
30-12	4906-4907	,	_	_	_	_
30-13	4908-4911	and	_	_	_	_
30-14	4912-4916	that	_	_	_	_
30-15	4917-4920	our	person|abstract[255]	giv|giv[255]	ana	31-18
30-16	4921-4928	results	abstract[255]	giv[255]	_	_
30-17	4929-4932	are	_	_	_	_
30-18	4933-4936	not	_	_	_	_
30-19	4937-4950	generalizable	_	_	_	_
30-20	4951-4953	to	_	_	_	_
30-21	4954-4962	patients	person	giv	coref	30-31[260_0]
30-22	4963-4966	who	_	_	_	_
30-23	4967-4978	discontinue	_	_	_	_
30-24	4979-4988	treatment	event	giv	_	_
30-25	4989-4995	within	_	_	_	_
30-26	4996-4999	six	time[258]	giv[258]	coref	31-12[267_258]
30-27	5000-5006	months	time[258]	giv[258]	_	_
30-28	5007-5010	for	time[258]	giv[258]	_	_
30-29	5011-5025	intolerability	time[258]|abstract	giv[258]|new	_	_
30-30	5026-5028	or	time[258]	giv[258]	_	_
30-31	5029-5037	patients	time[258]|person[260]	giv[258]|giv[260]	_	_
30-32	5038-5042	with	time[258]|person[260]	giv[258]|giv[260]	_	_
30-33	5043-5048	early	time[258]|person[260]|abstract[262]	giv[258]|giv[260]|giv[262]	_	_
30-34	5049-5052	ACC	time[258]|person[260]|abstract|abstract[262]	giv[258]|giv[260]|giv|giv[262]	coref	31-25[271_0]
30-35	5053-5063	recurrence	time[258]|person[260]|abstract[262]	giv[258]|giv[260]|giv[262]	_	_
30-36	5064-5065	.	_	_	_	_

#Text=The inclusion criteria of the study produced an immortal time of six months that may have enriched our series of a higher number of low-risk ACC compared to recently published series .
31-1	5066-5069	The	abstract[264]	giv[264]	_	_
31-2	5070-5079	inclusion	person|abstract[264]	giv|giv[264]	_	_
31-3	5080-5088	criteria	abstract[264]	giv[264]	_	_
31-4	5089-5091	of	abstract[264]	giv[264]	_	_
31-5	5092-5095	the	abstract[264]|abstract[265]	giv[264]|giv[265]	_	_
31-6	5096-5101	study	abstract[264]|abstract[265]	giv[264]|giv[265]	_	_
31-7	5102-5110	produced	_	_	_	_
31-8	5111-5113	an	time[266]	new[266]	_	_
31-9	5114-5122	immortal	time[266]	new[266]	_	_
31-10	5123-5127	time	time[266]	new[266]	_	_
31-11	5128-5130	of	time[266]	new[266]	_	_
31-12	5131-5134	six	time[266]|time[267]	new[266]|giv[267]	_	_
31-13	5135-5141	months	time[266]|time[267]	new[266]|giv[267]	_	_
31-14	5142-5146	that	_	_	_	_
31-15	5147-5150	may	_	_	_	_
31-16	5151-5155	have	_	_	_	_
31-17	5156-5164	enriched	_	_	_	_
31-18	5165-5168	our	person|abstract[269]	giv|new[269]	coref	31-29[272_269]
31-19	5169-5175	series	abstract[269]	new[269]	_	_
31-20	5176-5178	of	abstract[269]	new[269]	_	_
31-21	5179-5180	a	abstract[269]|abstract[270]	new[269]|new[270]	_	_
31-22	5181-5187	higher	abstract[269]|abstract[270]	new[269]|new[270]	_	_
31-23	5188-5194	number	abstract[269]|abstract[270]	new[269]|new[270]	_	_
31-24	5195-5197	of	abstract[269]|abstract[270]	new[269]|new[270]	_	_
31-25	5198-5206	low-risk	abstract[269]|abstract[270]|abstract[271]	new[269]|new[270]|giv[271]	_	_
31-26	5207-5210	ACC	abstract[269]|abstract[270]|abstract[271]	new[269]|new[270]|giv[271]	_	_
31-27	5211-5219	compared	_	_	_	_
31-28	5220-5222	to	_	_	_	_
31-29	5223-5231	recently	abstract[272]	giv[272]	_	_
31-30	5232-5241	published	abstract[272]	giv[272]	_	_
31-31	5242-5248	series	abstract[272]	giv[272]	_	_
31-32	5249-5250	.	_	_	_	_
